Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease

被引：203

作者：

Rosenson, Robert S. ^{[1
]}

Davidson, Michael H. ^{[2
]}

Hirsh, Benjamin J. ^{[3
]}

Kathiresan, Sekar ^{[4
]}

Gaudet, Daniel ^{[5
,6
]}

机构：

[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[2] Univ Chicago, Pritzker Sch Med, Div Cardiol, Chicago, IL 60637 USA

[3] Mt Sinai Hosp, New York, NY 10029 USA

[4] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA

[5] Univ Montreal, Dept Med, ECOGENE 21, Chicoutimi, PQ, Canada

[6] Univ Montreal, Dept Med, Lipid Clin, Chicoutimi, PQ, Canada

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2014年 / 64卷 / 23期

关键词：

atherosclerosis; cardiovascular disease; genetics; triglyceride; triglyceride-rich lipoproteins; LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; APOLIPOPROTEIN C-III; ALIPOGENE TIPARVOVEC AAV1-LPLS447X; TISSUE-SPECIFIC EXPRESSION; CYTOSOLIC LIPID DROPLETS; GENOME-WIDE ASSOCIATION; EXTENDED-RELEASE NIACIN; NONFASTING TRIGLYCERIDES; SEVERE HYPERTRIGLYCERIDEMIA;

D O I：

10.1016/j.jacc.2014.09.042

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Triglycerides represent 1 component of a heterogeneous pool of triglyceride-rich lipoproteins (TGRLs). The reliance on triglycerides or TGRLs as cardiovascular disease (CVD) risk biomarkers prompted investigations into therapies that lower plasma triglycerides as a means to reduce CVD events. Genetic studies identified TGRL components and pathways involved in their synthesis and metabolism. We advocate that only a subset of genetic mechanisms regulating TGRLs contribute to the risk of CVD events. This " omic" approach recently resulted in new targets for reducing CVD events. (C) 2014 by the American College of Cardiology Foundation.

引用

页码：2525 / 2540

页数：16

共 50 条

[21] Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?
Dallinga-Thie, Geesje M.
Kroon, Jeffrey
Boren, Jan
Chapman, M. John
CURRENT CARDIOLOGY REPORTS, 2016, 18 (07)
[22] Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk
Nordestgaard, Borge G.
Tybjaerg-Hansen, Anne
CURRENT OPINION IN LIPIDOLOGY, 2011, 22 (02) : 113 - 122
[23] Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk
Baratta, Francesco
Cocomello, Nicholas
Coronati, Mattia
Ferro, Domenico
Pastori, Daniele
Angelico, Francesco
Ben, Maria Del
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (05)
[24] Triglyceride-rich lipoproteins and progression of atherosclerosis
Hodis, HN
Mack, WJ
EUROPEAN HEART JOURNAL, 1998, 19 : A40 - A44
[25] Role of triglyceride-rich lipoproteins in diabetic nephropathy
Rutledge, John C.
Ng, Kit F.
Aung, Hnin H.
Wilson, Dennis W.
NATURE REVIEWS NEPHROLOGY, 2010, 6 (06) : 361 - 370
[26] Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
Boren, Jan
Taskinen, Marja-Riitta
Bjornson, Elias
Packard, Chris J.
NATURE REVIEWS CARDIOLOGY, 2022, 19 (09) : 577 - 592
[27] Metabolism of triglyceride-rich lipoproteins and their role in atherosclerosis
Tanaka, A
Ai, M
Kobayashi, Y
Tamura, M
Shimokado, K
Numano, F
ATHEROSCLEROSIS VI, 2001, 947 : 207 - 213
[28] Triglyceride-Rich Lipoproteins as a Source of Proinflammatory Lipids in the Arterial Wall
Oorni, Katariina
Lehti, Atu
Sjovall, Peter
Kovanen, Petri T.
CURRENT MEDICINAL CHEMISTRY, 2019, 26 (09) : 1701 - 1710
[29] Triglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease
Duran, Edward K.
Pradhan, Aruna D.
CLINICAL CHEMISTRY, 2021, 67 (01) : 183 - 196
[30] Leukocyte activation by triglyceride-rich lipoproteins
Alipour, Arash
van Oostrom, Antonie J. H. H. M.
Izraeljan, Alisa
Verseyden, Caroline
Collins, Jennifer M.
Frayn, Keith N.
Plokker, Thijs W. M.
Elte, Jan Willem F.
Cabezas, Manuel Castro
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (04) : 792 - 797

← 1 2 3 4 5 →